COVID-19 vaccine: Akston Biosciences doses first volunteers in Phase II/III trial – Business Today

The multicenter trial will complete the enrollment of 1500 healthy volunteers, age 18 and older, who will receive two 90 µg doses 28 days apart, … Read source

Click to rate this post!
[Total: 0 Average: 0]
Scroll to Top